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Abstract
Background: Antiretroviral therapy for HIV in sub-Saharan Africa has transformed the highly infectious virus to a stable chronic
condition, with the advent of Highly active antiretroviral therapy (HAART). The longterm effects of HAART on the oral health of children
are understudied.
Objective: To compare the effect of lopinavir-ritonavir and lamivudine on oral health indicators (dental caries, gingivitis, tooth
eruption, and oral health related quality of life) in 5 to 7 year old HIV-1 exposed uninfected children from the ANRS 12174 trial.
Methods: This study used data collected in 2017 among children aged 5 to 7 years from the Ugandan site of the ANRS 12174
randomized trial (ClinicalTrials.gov no: NCT00640263) implemented between 2009 and 2012 in Mbale district, Eastern Uganda. The
intervention was lopinavir-ritonavir or lamuvudine treatment to prevent vertical HIV-1 transmission. One hundred thirty-seven and 139
children were randomized to receive lopinavir-ritonavir or lamivudine treatment at day 7 postpartum to compare efficacy of prevention
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of vertical HIV-1 transmission. At follow up, the children underwent oral examination using theWorld Health Organization methods for
field conditions. The oral health related quality of life was assessed using the early childhood oral health impact scale. Negative
binomial and logistic regression were used for the analysis of data.
Main outcomemeasures:Dental caries, gingivitis, tooth eruption, and oral health related quality of life) in 5 to 7 year old HIV-1
exposed uninfected children.
Results:The prevalence of dental caries was 48% in the study sample: 49% in the lopinavir-ritonavir arm and 48% in the lamivudine
treatment group. The corresponding mean decayed missing filled teeth and standard deviation was 1.7 (2.4) and 2.3 (3.7) The mean
number (standard deviation) of erupted permanent teeth was 3.8 (3.7) and 4.6 (3.9) teeth in the lopinavir- and lamivudine group,
respectively. The prevalence of reported impacts on oral health was 7% in the lopinavir-ritonavir and 18% in the lamivudine group.
Gingivitis had a prevalence of 7% in the lopinavir-ritonavir and 14% lamivudine treatment group. The regression analysis revealed
70% less reported impacts on oral health in lopinavir-ritonavir group than the lamivudine treatment group with an incidence rate ratio
of 0.3 (95% confidence interval: 0.1–0.9).
Conclusions: HIV exposed uninfected infants in the lopinavir-ritonavir group reported less impacts on oral health than the
lamivudine treatment group. Dental caries, gingivitis, and tooth eruption were not significantly affected by the treatment lopinavir-
ritonavir or lamivudine.
Trial Registration ClinicalTrials.gov identifier: NCT00640263.
Abbreviations: ART = antiretroviral treatment, cART = combined antiretoviral treatment, CI = confidence interval, dmft/s =
decayed missing filled teeth/surfaces, HAART = highly active antiviral treatment, HIV = human immune virus, IRR = incidence rate
ratio, OHRQoL = oral health related quality of life, PIs = protease inhibitors, PROMISE-PEP = promoting infant health and nutrition in
Sub African Africa: safety and efficacy-pre exposure propylaxis, REC = Regional Ethical Committee.
Keywords: antiretroviral, children, clinical trial, dental caries, gingivitis, oral health related quality of life, public health
1. Introduction
Human immune virus (HIV) treatment programs in sub-Saharan
Africa have transformed HIV infection from being a highly lethal
infectious disease to a condition with many similarities to other
chronic diseases.[1] Especially, the introduction of highly active
antiretroviral therapy (HAART) using 3 or more antiretroviral
drugs in combination, has led to significant declines in HIV-
associated morbidity and mortality.[2] Among the commonly
used antiretroviral drugs are the nucleoside reverse transcriptase
inhibitor like lamivudine and the protease inhibitors (PIs) like
lopinavir-ritonavir.[3] Both drugs have been used as first- or
second-line treatment options, for children, adolescents, and
adults.[4,5]
It is important to investigate the long-term safety aspects of
antiretroviral drug regimens in order to maximise control of HIV
while at the same time minimizing adverse events. The ANRS
12174 multi-center trial investigated consequences of providing
lopinavir/ritonavir versus lamivudine to exposed uninfected
infants and reported less weight gain at 50 weeks among infants
given lopinavir–ritonavir compared to infants receiving lamivu-
dine. This indicates a negative growth effect that could have
adverse health- and developmental consequences among infants
given lopinavir-ritonavir.[6] Recently, another study from ANRS
12174 found that lopinavir-ritonavir was associated with dose-
dependent adrenal dysfunction in infants.[7]
A study from Iran compared adult persons with HIV receiving
HAART to HAART naïve controls and reported no differences
related to crown and root caries.[8] Similar conclusions were also
reported from the United states in an HIV cohort of women.[9]
However, from Thailand it has been reported that HIV infected
adults with long-term use of HAART (commonly non PI based
regimens) showed a greater risk of having gingival bleeding on
probing and oral lesions than their counterparts on short – term
HAART.[10] In contrast, Bretz et al found that adult patients who
received antiretroviral therapy (ART) had a less occurrence of
dental caries than patients not taking these medications.[11] The
studies involving children with regard to HIV infection have
focused on reporting the prevalence of oral lesions and not the
effect of HAART on oral health outcomes These studies reported
high prevalence of dental caries.[12,13] However 1 study from the
Unites States involving youth aged between 10 and 18 years
explored the association between combination antiretroviral
therapy (cART) and oral health outcomes (dental and periodon-
tal) lesions and found that youth who had received combination
antiretroviral treatment containing integrase inhibitors had
significantly higher number of teeth with untreated active caries
than those with cART without intergrase inhibitors. This study
also found that the youth with later initiation of PIs had
significantly higher decayed, missing filled teeth/surfaces (DMFT/
S) scores than the youth initiating PI at an earlier stage.[14] Other
oral health conditions like reduced salivary flow rates and
salivary gland engorgement have also been associated with
HAART and specifically with PI based HAART.[10,15]
The literature regarding the association of HAART with oral
conditions shows mixed findings. The long-term impact of
exposure to HAART on children’s oral health status is under-
studied and requires more documentation. The purpose of this
study was to compare the effect of lopinavir-ritonavir and
lamivudine on oral health indicators (dental caries, gingivitis,
tooth eruption, and oral health related quality of life) of 5 to 7
year old HIV exposed uninfected children from the ANRS 12174
trial.
2. Methods
2.1. Study setting and design
This study presents data for analysis of secondary outcomes from
the Ugandan mother-children pairs participating in the ANRS
12174 randomized trial (ClinicalTrials.gov no: NCT00640263)
implemented between 2009 and 2012 and the ANRS 12341
follow-up study carried out between March 2017 and February
2018 in Mbale district, Eastern Uganda.[16]
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In summary, the ANRS 12174 promoting infant health and
nutrition in Sub African Africa: safety and efficacy-pre exposure
propylaxis (PROMISE-PEP) trial was a multicenter randomized
trial recruiting women in antenatal clinics at 4 African sites:
Ouagadougou University Teaching Hospital (urban site in
Burkina Faso), East London Hospital Complex (urban site in
South Africa); Mbale Regional Referral Hospital (semi-rural site
in Uganda); and Lusaka University Teaching Hospital (urban site
in Zambia). The aim was to compare lopinavir–ritonavir with
lamivudine (given from day 7 after birth until either 50weeks or 1
week after cessation of breastfeeding) on the rate of HIV-1
transmission and adverse events among HIV-1-exposed unin-
fected infants in Africa. The participating mothers followed
routine national prevention guidelines until day 7 postpartum
when their new-borns were randomized to either lopinavir–
ritonavir (Kaletra, Abbott, Chicago) or generic lamivudine.
Detailed information about this trial has been published
previously.[17] The inclusion criteria for the infants were: being
singleton; breastfed at day 7 by their mothers; a negative HIV-1
DNA PCR at day 7; and having received any prevention of
mother to child treatment. For the mothers the criteria were:
being 18 years or older, having intention to continue breastfeed-
ing, HIV-1 infected, and not eligible for ART at the time of the
study (clinically determined or because CD4 count<350 cells per
mL), not intending to move out of the area in the next year, and
gave consent to participate for herself and her infant. The
exclusion criteria were: new-borns who had clinical signs or
biological abnormalities of grade 2 or higher on the US National
Institutes of Health Division of AIDS adverse events grading
tables, with exceptions for hemoglobin (not included if
hemoglobin <120g/L) and absolute neutrophil count (not
included if neutrophils <1200 cells per mL [1.20109/L]); or
if they presented with serious congenital malformations or
birthweight was 2.0kg or lower.
During the ANRS 121741 PROMISE- PEP trial 7 day old
babies were randomized to the lopinavir–ritonavir or lamivudine
in a 1:1 ratio (Fig. 1). The study participants and data collectors,
data managers, and statisticians were masked to the allocation
arm. However, given the poor palatability of lopinavir-ritonavir,
some parents might have known their child’s treatment
allocation. The infants received locally available pediatric liquid
formulations of either lopinavir–ritonavir (Kaletra, Abbott);
40mg of Lopinavir and 10mg of ritonavir, twice a day if
weighing 2 to 4kg, and 80mg and 20mg, twice a day if weighing
>4kg) or generic lamivudine (7.5mg twice a day if weighing
2–4kg, 25mg twice a day if weighing 4–8kg, and 50mg twice a
day if weighing >8kg).
Two hundred seventy-six infants were recruited to the
Ugandan site of the ANRS 121741 PROMISE-PEP trial with
137 (50%) randomized to lopinavir–ritonavir and 139 (50%) to
lamivudine. In 2017, in a follow-up visit at the age of around
6 years, 166 children were followed-up. Two of the children were
excluded due to HIV seroconversion with 164 eligible for
enrollment. The loss to follow-up was 42% and 40% in the
Lopinavir-ritonavir and lamivudine groups, respectively. The
reasons for loss to follow were relocation and child deaths
(Fig. 1).
2.2. Primary outcomes
The outcomes of this study were: dental caries experience,
gingivitis, oral health related quality of life, number of retained
primary and erupted permanent teeth.
2.3. Interview with mothers at baseline
(7 days post-partum) and follow-up (2017)
Data at baseline and follow-up was collected using semi-
structured interviews with mothers in the local language
(Lumasaaba). Details of data collection and capture are
described elsewhere.[16,18] The oral health questionnaire used
at follow-up has been developed and tested previously in a
similar population.[19] The oral health data was entered in
Epidata software (www.epidata.dk). The interview schedule
included questions about socio-demographic characteristics in
terms of age, sex, marital status, level of education, and type of
income. A wealth index based on ownership of household
assets, such as furniture, electricity, type of water source, roof
material, and type of toilet assessed at the baseline interview,
was constructed and categorized into wealth quintiles. This
socio-economic asset index was initially categorized into
quintiles ranging 1 to 5 (most poor–least poor) and then
recoded into the 2 categories (ie, the poorest and least poor) for
analysis. The oral health related quality of life (OHRQoL) was
assessed at follow up in 2017 using.[20] a slightly modified and
abbreviated version of the Early ChildhoodOral Health Impact
Scale scale previously assessed for its psychometric properties
among preschool children in Uganda.[21] The scale, consists of
the child impact section and family impact section, which are
proxy measures of children’s OHRQoL with parents as
respondents to assist children in evaluating their own quality
of life. The child impact section, was assessed using 5 of its
original 9 questions, covering the original 4 subdomains:
symptoms, function, psychology, self-image, and child social
interaction. The family impact section was assessed using the
original 4 questions covering 2 domains of family distress and
family function. Response categories were rated on a 5-point
Likert scale. Total OHRQoL scores were constructed by adding
the Child and Family impact scores. A dichotomy variable in
terms of “0” equal to no total OHRQoL impact and “1” equal
to at least 1 OHRQoL impact was constructed for analyses.
Figure 1. Trial profile.
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2.4. Clinical oral examination of children at follow-up visit
(2017)
The clinical oral examination was performed by 2 experienced
dental surgeons (NB and MM). Dental caries were assessed on
fully erupted primary teeth using the decayed, missing, and filled
teeth index (dmft) in accordance with the World Health
Organization guidelines for field conditions.[22] A tooth was
documented as decayed if it was visually cavitated with the aid of
a dental mirror and periodontal probe. A tooth was qualified as
missing when extracted due to caries, as confirmed by themother.
In the present analysis, dmft was used as a count variable and a
dichotomous variable. The count variable was the sum of the
decayed, missed or filled teeth. The dichotomized variable was
categorized as absent for dmft count equal to “0” and present for
dmft count greater than “0.” To assess gingivitis of the children,
the modified community periodontal index was used.[22] Each
tooth was scored according to the presence or absence of gingival
bleeding, indicative of presence or absence of gingival inflamma-
tion, using a periodontal probe across the gingival margins of the
teeth.
The retained primary teeth and permanent dentition were
assessed by manually counting the retained primary and fully
erupted permanent teeth.
2.5. Reliability measurements
Duplicate clinical examinations were carried out after 2 weeks by
dental surgeons (NB and MM) with 26 children not involved in
the original study cohort but considered to be representative of
the study participants. The calibration exercise comparing dmft
scores for each primary tooth within and between examiners
revealed intra- and inter-rater reliability of median Kappa
(interquartile range) of 0.6 (0.5–0.7) and 0.7 (0.5–0.8),
respectively. The corresponding scores for the DMFT of
caregivers were 0.7 (0.5–0.9) and 0.6 (0.4–0.8), respectively.
2.6. Data cleaning and statistical analysis
The statistical package Stata/SE 16 (Stata Corp LLC, College
Station, TX) was used for analysis. To compare baseline
characteristics at randomization in the study sample at follow-
up, means for continuous and proportions for categorical
variables were used. Negative binomial regression with incidence
rate ratio (IRR) and 95% confidence intervals (CIs) was used to
assess the effect of lopinavir-ritonavir or lamivudine on dmft
count and OHRQOL impacts. Logistic regression with odds
ratios and 95% CIs was used to assess the effect of lopinavir-
ritonavir or lamivudine on gingivitis, OHRQoL, and dental
caries experience (dmft>0). To adjust for potential differences in
loss-to-follow- up between study groups an inverse probability
weight method with a probit regression was used to predict risk
of lost-to-follow-up based on social economic position, years of
education, and site of residence. The median of the inverse
probability weight was 1.8
2.7. Ethics
Ethical approval for the study was granted by the Makerere
University School of Medicine Research Ethics Committee (REC
REF 2018-030) and the Uganda National Council for Science
and Technology (HS 2373), and Regional Committees for
Medical and Health Research Ethics, Western Norway [(REK)
(2017/760/REC Sør-Øst)]. Signed or thumb-printed informed
consent was obtained from each mother before study participa-




The baseline characteristics of the 164 children analyzed at
follow-up, paralleled those at baseline and there were similar
numbers of participants in the lopinavir–ritonavir (n=80) and
lamivudine (n=84) treatment groups, respectively. With regard
to loss to follow-up, the number lost was similar across the
treatment groups with respect to both the categorical and
continuous variables. However, loss to follow up was more likely
among slightly younger women and women with higher viral
load. Median maternal age (interquartile range) in the study
group at baseline was 27 (23–28) and 28 (23–30) in the lopinavir-
ritonavir and lamivudine treatment groups, respectively. Corre-
sponding figures among those lost to follow up were 25 (23–28)
and 25 (22–28) years. The viral load in the study group at
baseline was 150 (150–338) and 150 (150–1396) viral copies/mL
in the lopinavir-ritonavir and lamivudine treatment groups,
respectively. Corresponding figures among those lost to follow up
were 228 (150–3376) and 293 (150–3476) viral copies/mL
(Table 1).
As indicated in Table 2, the average age of the children at
followwas 6 years across the treatment groups. The prevalence of
dental caries was 48% (dmft >0) in the total study group and
49% and 48% in the lopinavir-ritonavir and lamivudine
treatment groups, respectively. The corresponding mean dmft
and standard deviation values were 1.7 (2.4) and 2.3 (3.7). The
pattern of mean dmft was similar across the treatment groups
with most of anterior teeth in the upper jaw and molars depicting
higher frequency as is the usual pattern of dmft experience
(Fig. 2). The average number of retained primary teeth was
comparable across treatment groups and amounted to 17 teeth.
The lopinavir group had on average a lower number of erupted
permanent teeth than the lamivudine group with a mean number
(standard deviation) of 3.8 (3.7) and 4.6 (3.9) teeth, respectively
(Fig. 3). A small percentage of mothers, (13%), reported impacts
on oral health, with 7% and 18% in the lopinavir-ritonavir and
lamivudine groups, respectively. The prevalence of gingival
bleeding was 12% in the study sample with 7% and 14%
in the lopinavir-ritonavir and lamivudine treatment groups,
respectively.
Negative binomial regression did not indicate statistically
significant differences between the treatment groups with respect
to dental caries experience, gingivitis, retained primary teeth, and
erupted permanent teeth. The corresponding IRRs, with 95%CIs
were 0.7 (0.4–1.3), 0.3 (0.05–1.8) and 0.8 (0.6–1.2), respectively.
There were 70% less impacts reported in lopinavir-ritonavir
group than in the lamivudine treatment group with IRR of 0.3
(95% CI: 0.1–0.9) (Table 3).
Logistic regression showed no significant differences between
the treatment groups with respect to dental caries experience,
gingivitis, and oral health related quality of life. The correspond-
ing odds ratio (95% CIs): were 1.0 (0.6–2.0), 0.6 (0.2–1.5) and
0.4 (0.1–1.0) respectively (Supplemental Digital Content [Addi-
tional file], Table SI, http://links.lww.com/MD/E914).
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4. Discussion
According to the present findings, having received lopinavir-
ritonavir or lamivudine during the trial period did not have a
significant long term effect on children’s dental caries experience,
gingivitis, the number of retained primary- and erupted
permanent teeth at follow-up. In contrast, children receiving
lopinavir-ritonavir were less likely than their counterparts
receiving lamivudine to experience oral impacts or reduced oral
health related quality of life at follow up.
The random assignment of children is a strength of this study as
randomized trial designs minimize the risk of confounding.
Furthermore, the dental examiners and research assistants were
blind to the allocation status of study participants limiting
possible measurement bias.
Due to the long follow-up time, there was attrition, which
reduced the sample size. This could have led to unequal groups
and a problem with differential loss to follow up. However, we
compared baseline characteristics in the available study sample
and those lost to follow-up and as reported the treatment groups
remained comparable indicating that the randomization had
been maintained. Also, the reduced sample size could involve the
epidemiological possibility of type II errors. The non-statistically
significant differences were predominantly smaller. We acknowl-
edge the limitation that assessment of dental caries at cavity level
under field conditions without using x-rays might lead to
underestimation of dental caries prevalence as the early incipient
lesions are left out.
It is difficult to compare the findings of this study with other
studies. This is because most of the literature focuses on persons
withHIV infected on ARTwhile our study involvedHIV exposed
uninfected children who had received lopinavir-lopinavir or
lamuvudine to prevent vertical transmission. A study from the US
focusing on the effect of cART on oral outcomes (dental caries
Table 1







n (%) n (%) n (%) n (%)
Eligible mother infant pairs 80 (49) 84 (51) 57 (42) 55 (39)
Marital status
Married/cohabiting 69 (86) 73 (87) 42 (73) 42 (76)
Socio-economic status quintile
1–2 (poorest) 52 (65) 51 (61) 47 (82) 41 (75)
3–5 28 (35) 33 (39) 10 (17) 13 (24)
Education level
None 4 (5) 3 (3) 4 (7) 2 (4)
Primary 48 (60) 47 (56) 34 (60) 34 (63)
Secondary or more 28 (35) 34 (40) 19 (33) 18 (3
HIV clinical staging
Stage I 75 (94) 75 (89) 52 (91) 52 (94)
Stage II 5 (6) 8 (9) 5 (9) 3 (5)
Stage III 0 (0) 1 (1) 0 (0) 0 (0)
Detectable viral load
Yes 58 (72) 50 (63) 33 (57) 34 (64)
Child sex
Girls 42 (52) 40 (47) 34 (60) 30 (54)
Continuous data Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Maternal median age (yr) 27 (23–30) 28 (23–30) 25 (23–28) 25 (22–28)
Maternal body -mass index
day 7 (kg/m2)
23 (21–24) 23 (20–24) 22 (20–24) 22 (21–25)
Maternal CD4 cell count day 7 523 (432–617) 527 (441–612) 524 (417–643) 515 (418–6625)
Maternal HIV viral copies/mL 150 (150–338) 150 (150–1396) 228 (150–3376) 293 (150–3476)
Child median birth weight (grams) 3000 (2750–3300) 3100 (2930–3350) 3000 (2700–3300) 3000 (2800–3400)
IQR= interquartile range.
Table 2
Summary data; mean, standard deviation (SD), number (n), and






Variable n (%) n (%)
Continuous variables (mean, SD)
Mean child age (SD) 6.0 (0.7) 6.0 (0.8) 6.0 (0.5)
Mean no of erupted
permanent teeth (SD)
4.2 (3.8) 3.8 (3.7) 4.6 (3.9)
Mean no of retainedprimary
teeth (SD)
17 (7.2) 17 (2.4) 17 (9.8)
dmft
∗
score 2.0 (3.2) 1.7 (2.4) 2.3 (3.7)
Categorical n (%)
dmft >0
Yes 79 (48%) 39 (49) 40 (48)
Gingival bleeding present
Yes 19 (12) 7 (9) 12 (14)
Child impact score >0
Yes 19 (12) 5 (6) 14 (17)
Family impact score >0o
Yes 11 (7) 2 (2) 9 (11)
Child and family impact score >0
Yes 21 (13) 6 (7) 15 (18)
∗
Decayed, missing filled teeth.
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and periodontal) found that perinatally HIV infected youth
initiated later on PIs had significantly higher DMFT/S scores than
periantally HIV youth initiated to the PIs at an earlier age.[14]
However, this study unlike our study whose children were taking
HAART as prophlaxis to prevent vertical transmission, excluded
children who were taking HAART as propylaxis Thus, our study
is one of the first to investigate the potential effect of antiretroviral
drugs on children’s oral health independent of HIV infection.
So far research findings are mixed with some studies
indicating that HAART is not associated with dental caries[8,9]
while other studies have found both negative[11] and positive
associations between HIV infected people on HAART and dental
Figure 2. Distribution of mean dmft (decayed, missing filled teeth) by tooth type in the maxilla for lopinavir-ritonavir (top left) and lamivudine (top right) group. Also
distribution of mean dmft in mandible lopinavir-ritonavir (bottom left) and lamivudine group (bottom right).
Figure 3. Average numbers of retained primary teeth and erupted permanent teeth in lopinavir-ritonavir and lamivudine treatment groups.
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caries.[10,23,24] Thus, Kalanzi et al and Glick et al published case
reports that recommended further studies. In other studies
involving the ANRS 12174 trial participants, Blanche et al
observed less weight gain in infants given lopinavir–ritonavir
while Kariyawasam et al. found lopinavir–ritonavir to be
associated with dose dependent adrenal dysfunction.[7]
A possible explanation for lesser-reported oral impacts
reported in the lopinavir-ritonavir group could be due to higher
prevalence of gingivitis, dental caries, and number of teeth in the
lamivudine group compared to the lopinavir-ritonavir group
although this was not statistically significant. It has been
established in the literature that oral health impacts are
associated with clinical findings but is also influenced by social
and cultural factors.[21,25]
Further research is recommended to further clarify the
relationship of HAART on oral health of children.
5. Conclusions
HIV exposed uninfected infants in the lopinavir-ritonavir group
reported less impacts on oral health than their counterparts in the
lamivudine treatment group. Dental caries, gingivitis, and tooth
eruption were not significantly affected by lopinavir-ritonavir or
lamivudine pre exposure prophylaxis.
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